JP2020509018A - 養子細胞移植療法と併せてインターロイキン−2受容体α,β−選択的作動薬を用いる免疫療法的治療方法 - Google Patents
養子細胞移植療法と併せてインターロイキン−2受容体α,β−選択的作動薬を用いる免疫療法的治療方法 Download PDFInfo
- Publication number
- JP2020509018A JP2020509018A JP2019547077A JP2019547077A JP2020509018A JP 2020509018 A JP2020509018 A JP 2020509018A JP 2019547077 A JP2019547077 A JP 2019547077A JP 2019547077 A JP2019547077 A JP 2019547077A JP 2020509018 A JP2020509018 A JP 2020509018A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor
- acting
- long
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000556 agonist Substances 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title claims abstract description 80
- 238000002054 transplantation Methods 0.000 title abstract description 67
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 17
- 230000001024 immunotherapeutic effect Effects 0.000 title description 4
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 title 1
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 209
- 201000011510 cancer Diseases 0.000 claims abstract description 66
- 108010002350 Interleukin-2 Proteins 0.000 claims description 145
- 102000000588 Interleukin-2 Human genes 0.000 claims description 145
- 238000011282 treatment Methods 0.000 claims description 103
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 80
- 229920001223 polyethylene glycol Polymers 0.000 claims description 50
- 108700025316 aldesleukin Proteins 0.000 claims description 42
- 229960005310 aldesleukin Drugs 0.000 claims description 41
- 210000003289 regulatory T cell Anatomy 0.000 claims description 38
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 31
- 239000002202 Polyethylene glycol Substances 0.000 claims description 23
- 230000004044 response Effects 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 20
- 238000001727 in vivo Methods 0.000 claims description 17
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 13
- 125000003827 glycol group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000012636 effector Substances 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 9
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000000717 retained effect Effects 0.000 claims description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 6
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 6
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000010171 animal model Methods 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 22
- 210000004027 cell Anatomy 0.000 description 143
- 239000003981 vehicle Substances 0.000 description 38
- 210000004698 lymphocyte Anatomy 0.000 description 33
- 229920000642 polymer Polymers 0.000 description 28
- 201000001441 melanoma Diseases 0.000 description 24
- 210000000952 spleen Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 238000011467 adoptive cell therapy Methods 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 230000004614 tumor growth Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 108091008874 T cell receptors Proteins 0.000 description 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 210000002865 immune cell Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000003364 immunohistochemistry Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000002688 persistence Effects 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 238000002619 cancer immunotherapy Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 6
- 208000012766 Growth delay Diseases 0.000 description 6
- 108090000172 Interleukin-15 Proteins 0.000 description 6
- 102000003812 Interleukin-15 Human genes 0.000 description 6
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 6
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 6
- 108010002586 Interleukin-7 Proteins 0.000 description 6
- 102000000704 Interleukin-7 Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 201000005112 urinary bladder cancer Diseases 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000029918 bioluminescence Effects 0.000 description 5
- 238000005415 bioluminescence Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000006023 anti-tumor response Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- -1 carboxylate esters Chemical class 0.000 description 4
- 210000004970 cd4 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 3
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 102000055277 human IL2 Human genes 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000004983 pleiotropic effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000004488 maxillary sinus cancer Diseases 0.000 description 2
- 208000019303 maxillary sinus carcinoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 101150083678 IL2 gene Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011220 combination immunotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical group SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006323 depegylation Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000008759 sweat gland cancer Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000005737 synergistic response Effects 0.000 description 1
- 201000008753 synovium neoplasm Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本願は、米国特許法第119条(e)のもと、2017年3月1日に出願された米国仮特許出願第62/465,506号明細書、及び2017年4月3日に出願された米国仮特許出願第62/480,971号明細書の優先権の利益を主張するものであり、これらの仮特許出願の内容は参照により全体として本明細書に援用される。
特に上記の難題にもかかわらず、進行性転移癌において、チェックポイント阻害剤抗体を含め、有効な治療は少数しかないので、癌を治療するための養子細胞移植臨床試験での患者の登録は継続している。進行中の養子細胞移植試験には、種々のタイプの細胞増殖剤、移植細胞、患者コンディショニング、腫瘍溶解剤が含まれ;養子細胞移植を改善するためのあるアプローチには、TILの代わりに遺伝子改変末梢T細胞の移植が含まれる。TILプロトコールは一般的には、TIL単離のために腫瘍組織を切除するために患者が外科的手術を受けることを必要とし;一方で、T細胞養子細胞療法は、一般的には、患者が外科的手術を回避することが可能であり、遺伝子改変用の末梢T細胞を得るために患者は白血球フェレーシスのみを必要とする。このアプローチは、どの腫瘍抗原が存在し得るかという事前の知識を要する。さらに、今まで、遺伝子操作されたT細胞療法(CAR−T又はTCR)は、液性腫瘍に対してのみ有効であり、固形腫瘍には効果がなく、T細胞サブセット集団の問題が残っている。固形腫瘍は、TIL及びインターロイキン−2にのみ応答している。これらのアプローチでさえ、増殖細胞集団が制御性T細胞、ヘルパーT細胞及びエフェクターT細胞を含み得るので、インターロイキン−2により増殖させた細胞集団は明らかではない。これは、制御及びエフェクターT細胞を等しく増殖させる、天然のインターロイキン−2の多面的性質から生じる。
本明細書で使用されるとき、単数形「a」、「an」、及び「the」には、文脈上特に明確に指示されない限り複数の指示対象が含まれる。
有効抗腫瘍応答を誘導するための有望な治療にもかかわらず、養子細胞療法後、初期応答後に癌性腫瘍が再発することが多い。さらに、養子T細胞移植に対する現在のプロトコールは一般に、T細胞増殖を刺激し、維持するためにサイトカイン又は他の薬剤などの免疫刺激物質を必要とするが、このような刺激剤は、エフェクターT細胞及び制御性T細胞の両方を刺激し得る。現在の養子細胞移植ストラテジーに付随する欠点の少なくとも一部に対処するための試みにおいて、本明細書中で、エクスビボで増殖させた腫瘍反応性T細胞及びIL−2Rβ−活性化量の長時間作用型IL−2Rβ−バイアス作動薬を癌がある対象に投与することを含む方法が提供される。長い間、高用量IL−2などのサイトカインが養子細胞移植と併用されてきた一方で、このような治療の結果、毛細血管漏出症、点滴された細胞の持続性の欠如及び低応答率などの患者毒性が報告されている。さらに、臨床的に承認されているIL−2は、腫瘍におけるTregが所望の抗腫瘍応答を妨害する免疫抑制につながり得るように、それぞれIL−2Rβγ及びIL−2Rαβγ複合体を結合させることを通じて、腫瘍殺傷CD8+エフェクターT細胞(CD8T)並びに制御性T細胞(Treg)の両方を増殖させる。従って、これら及び他の欠点に照らして、抗腫瘍特性が改善されている、耐久性があり、再現性があり、有効な養子細胞移植に基づく癌療法を提供するために、さらなる強化が必要とされる。従って、本開示は、例示的なインビボ動物モデルで示されるように、少なくとも部分的には、長時間作用型IL−2R作動薬及びより具体的にはIL−2Rβ−バイアス作動薬の細胞に基づく治療及び投与を含む特に有利な治療薬の併用の探索に基づく。
エクスビボで増殖させた腫瘍反応性T細胞を、即ち癌特異的な免疫反応を刺激するために投与することを含む治療方法が本明細書中で提供される。本明細書中で提供される組成物及び方法は、特に、臨床及び研究の両方の適用で利用される。本明細書中に記載の方法に従い、種々の養子細胞移植療法を行い得、本開示は、この点に限定されない。理論により縛られるものではないが、養子細胞移植、例えばT細胞移植及び本明細書中で提供されるような長時間作用型IL−2Rαβ−バイアス作動薬の免疫活性化の相補的機序ゆえに、所望のT細胞反応を刺激するためにIL−2経路を介して(即ち、養子細胞移植とともに、長時間作用型IL−2Rαβ−バイアス作動薬を投与することを介して)抗腫瘍薬の転帰の改善が達成され得ると考える。
本明細書に記載される方法は、長時間作用型IL−2Rβバイアス作動薬の投与を含む。これに関連して、本開示は、その作動薬が同じインビトロモデルにおけるIL−2Rαβへの結合親和性よりも少なくとも5倍高い(より好ましくは少なくとも10倍高い)IL−2Rβへのインビトロ結合親和性を呈し、非修飾IL−2よりも少なくとも10倍有効なインビボ半減期(IL−2のインビボ消失に基づく半減期)を有する限り、いかなる特定の長時間作用型IL−2Rβバイアス作動薬にも限定されない。例として、IL−2に対する親和性を基準として計測することが可能である。この点で、実施例1で言及し、以下に記載のRSLAIL−2分子は、IL−2と比較して、IL−2Rαβに対する親和性の約60倍の低下を示すが、IL−2と比較して、IL−2Rβに対する親和性は僅か約5倍しか低下していない。従って、例示的な長時間作用型IL−2Rβ−バイアス作動薬はRSLAIL−2である。
本明細書に記載される長時間作用型IL−2Rβバイアス作動薬の特徴の少なくとも1つ以上に基づき、エクスビボで培養し、増殖させた、自家もしくは同種異系の抗腫瘍T細胞又は本明細書中に記載のような他の細胞を投与することにより長時間作用型IL−2Rβバイアス作動薬の投与前に癌患者において免疫応答を誘導し、続いて、免疫抑制Tregの活性化を担うIL2Rαサブユニットと相互作用する領域が遮断される長時間作用型IL−2Rβバイアス作動薬を投与して、それにより優れた治療有効性を達成するために有効な方法が本明細書中に提供される。
アルデスロイキンのものと同一のアミノ酸配列を有する組換えヒトIL−2をクローニングし、発現させ、使用して本明細書でRSLAIL−2と称される例示的な長時間作用型IL−2Rαβバイアス作動薬を調製した。
MPEG2−C2−FMOC−20KD−NHSによるRIL−2のPEG化
1.44mg/mlの精製rIL−2(106.4mL)を第1の容器に入れ、続いて53.6mLの製剤化緩衝液(10mM酢酸ナトリウム、pH4.5、5%トレハロース)を加えた。pHを測ると4.62であり、温度を測ると21.2℃であった。PEG試薬のC2−PEG2−FMOC−NHS−20K(国際公開第2006/138572号パンフレットに記載されるとおり利用可能)(13.1g)を第2の容器に入れ、続いて73.3mLの2mM HClを加えた。得られた溶液を手動で25分間かき混ぜた。第1の容器にホウ酸ナトリウム(0.5M、pH9.8)を加えてpHを約9.1に上昇させ、次にPEG試薬が入った第2の容器の内容物を1〜2分間かけて第1の容器に加えた。次に8.1mLの2mM HClを第2の容器に入れることによってリンスステップを行い、第1の容器に内容物を加えた。コンジュゲーション反応では、最終的なrIL−2濃度は0.6mg/mLであり、ホウ酸ナトリウム濃度は120mMであり、pHは9.1±0.2であり、温度は20〜22℃であった。試薬の活性(置換レベル)を調整した後のPEG試薬とrIL−2とのモル比は35:1であった。コンジュゲーション反応を30分間進行させ、75mLの2N酢酸の添加による酸性化反応(pHをほぼ4に降下させる)により停止させた。生成物を上記のとおりイオン交換クロマトグラフィーにより精製して主として4mer、5mer及び6mer(r−IL−2に放出可能に共有結合しているPEG試薬の数を指す(8mer及びそれより高度なPEG化は、クロマトグラフィーに関連する洗浄ステップの間に取り除かれた)の組成物を提供した。この組成物は、本明細書で「RSLAIL−2」と称する。
RSLAIL−2の受容体バイアス及び関連免疫療法特性
IL−2受容体に対する結合親和性及び免疫刺激プロファイルに関連する受容体バイアス:RSLAIL−2のIL−2Rα及びIL−2Rβへの親和性を表面プラズモン共鳴(Biacore T−100)により直接計測し、臨床的に利用可能なIL−2(アルデスロイキン)と比較した。EDC/NHS化学を使用して抗ヒト抗体(Invitrogen)をCM−5センサーチップの表面に結合させた。次にヒトIL−2Rα−Fc又はIL−2Rβ−Fc融合タンパク質のいずれかをこの表面にわたって捕捉リガンドとして使用した。酢酸塩緩衝液pH4.5に、5mMから始まるRSAIL−2及びその活性IL−2コンジュゲート代謝産物(1−PEG及び2−PEG−IL−2)の段階希釈物を作成した。これらの希釈物をリガンドに5分間結合させて、結合した反応単位(RU)を濃度に対してプロットし、EC50値を決定した。各IL−2受容体サブタイプに対する各アイソフォームの親和性をIL−2と比べた倍数変化として計算した。
RSLAIL−2の腫瘍曝露
本試験の目的は、アルデスロイキンと比較した場合の、B16F10黒色腫細胞を移植したC57BL/6マウスにおけるRSLAIL−2の抗腫瘍活性を評価することであった。
高悪性度マウス黒色腫モデルにおけるACTと併用したRSLAIL−2の抗腫瘍活性の評価
pmel−1 ACT/BL6黒色腫腫瘍モデルを使用して、RSLAIL−2の抗腫瘍活性を試験し、腫瘍特異的なTCRトランスジェニックT細胞におけるその効果を評価した。D6(6日目)における500cGyの線量のイオン化放射線でのリンパ球枯渇後、0日目(D0)に、C57/BL6マウスにB16−F10マウス黒色腫細胞を移植した。D7に、ACT(1μg/ml抗原gp100でインビトロにて活性化したTリンパ球)+RSLAIL−2(0.8mg/kg、q9dx3、i.v.)の併用、又はC57/BL6T細胞+PBS(ビヒクル対照)でマウスを治療した。ビヒクル対照マウス(n=12)の腫瘍は、治療後12日で1500mm3エンドポイントまで急速に成長したが、一方でRSLAIL−2/ACT併用群(n=12)では35日で1/12のみがエンドポイントに達した。生体発光イメージングを使用して、抗原特異的なT細胞のインビボでの分布及び腫瘍ホーミングを可視化した。興味深いことに、RSLAIL−2/ACT投与後、レポーターT細胞がD7まで脾臓で保持され、D9で腫瘍への移動が見られ得、D12で生体発光のピークに達し、従来のIL−2治療マウスで通常観察される5日と比較して遅れていた。ビヒクル対照動物の場合のD7に対して、D20までシグナルが保持された。これらのデータから、ACTと併用したRSLAIL−2が、高悪性度B16F10マウス黒色腫モデルにおいて、忍容性に優れ、ロバストな抗腫瘍応答を提供することが示唆される。RSLAIL−2及びACT療法での治療により、T細胞が腫瘍へとロバストに移動し、そこでT細胞が耐久的に存続する。RSLAIL−2のロバストで長時間持続する効果は、細胞に基づく治療とのその併用を裏付ける。
マウス黒色腫モデルにおけるACTと併用したRSLAIL−2又はIL−2の抗腫瘍活性の評価
D−7(−7日目)に、C57/BL6マウスの皮下にB16F10(0.5×106個/動物)同系マウス黒色腫細胞株を移植し、D−1(−1日)に500cGy線量のイオン化放射線でリンパ球を枯渇させた。D0(0日目)に、ACT(1μg/ml gp100によりインビトロで活性化したpmel−1 gp100 TCRトランスジェニックTリンパ球)及びRSLAIL−2(0.8mg/kg、q9dx3、i.v.)の併用で、又はIL−2(アルデスロイキン、0.4mg/kg、qdX3、9日ごと、3サイクル、i.p.)又はビヒクルでマウスを治療した。2回目及び3回目の治療サイクルにはACTを含めなかった。ビヒクル対照は実施例4と同じであった。図3は、使用した投与ストラテジーの模式的な説明を提供する。
Claims (32)
- 癌を有する対象を治療するための方法であって、
(i)前記対象から回収し、エクスビボで培養し、増殖させた腫瘍特異的な宿主T細胞を前記対象に投与することと、
(ii)長時間作用型IL−2Rβ−バイアス作動薬のIL−2Rβ−活性化量を前記対象に投与することと、
を含む方法。 - ステップ(i)及びステップ(ii)が、連続的にいずれかの順序で、又は実質的に同時に行われる、請求項1に記載の方法。
- ステップ(i)がステップ(ii)の前に行われる、請求項1に記載の方法。
- ステップ(ii)がステップ(i)の前に行われる、請求項1に記載の方法。
- ステップ(i)及び(ii)の両方が実質的に同時に行われる、請求項1に記載の方法。
- ステップ(i)及び(ii)が両方とも治療の1日目に行われる、請求項5に記載の方法。
- ステップ(ii)が、治療の1〜7日目のいずれか1日に行われる、請求項3に記載の方法。
- 治療過程にわたる、前記回収し、培養し、増殖させた腫瘍特異的な宿主T細胞の前記対象への単回投与を含む、請求項1〜7のいずれか一項に記載の方法。
- 治療過程にわたる、前記長時間作用型IL−2Rβ−バイアス作動薬のIL−2Rβ活性化量の前記対象への複数回投与を含む、請求項1〜7のいずれか一項に記載の方法。
- 前記回収し、培養し、増殖させた腫瘍特異的な宿主T細胞が点滴により投与される、請求項1〜9のいずれか一項に記載の方法。
- 前記腫瘍特異的な宿主T細胞が、腫瘍浸潤リンパ球(TIL)である、請求項1〜10のいずれか一項に記載の方法。
- 前記対象がヒトである、請求項1〜11のいずれか一項に記載の方法。
- 前記癌が固形癌である、請求項1〜12のいずれか一項に記載の方法。
- 前記癌が液性癌である、請求項1〜12のいずれか一項に記載の方法。
- 前記癌が転移性である、請求項13に記載の方法。
- 前記長時間作用型IL−2Rβ−バイアス作動薬が、4〜7個のポリエチレングリコール部分に放出可能に共有結合されるアルデスロイキンを含む、請求項1〜15のいずれか一項に記載の方法。
- 前記長時間作用型IL−2Rβ−バイアス作動薬が、4〜6個のポリエチレングリコール部分に放出可能に共有結合されるアルデスロイキンを含む、請求項16に記載の方法。
- 前記ポリエチレングリコール部分が分枝状である、請求項16又は請求項17に記載の方法。
- 前記分枝状ポリエチレングリコール部分が、中央のフルオレン環の2−及び7−位から延在するポリエチレングリコール鎖を含む、請求項18に記載の方法。
- 前記長時間作用型IL−2Rβ−バイアス作動薬が、式I
による化合物又はその薬学的に許容可能な塩を含む、請求項19に記載の方法。 - 各「n」が、約40〜約550の整数である、請求項20に記載の方法。
- 各「n」が約227である、請求項21に記載の方法。
- 前記長時間作用型IL−2Rβ−バイアス作動薬が、約10%(モル濃度量)以下の式II
による化合物又はその薬学的に許容可能な塩を含む、請求項20〜22のいずれか一項に記載の方法。 - 式Iによる長時間作用型IL−2Rβ−バイアス作動薬が、IL−2に放出可能に結合する平均約6個の分枝状ポリエチレングリコール部分を保持する、請求項20〜23のいずれか一項に記載の方法。
- 前記長時間作用型IL−2Rβ−バイアス作動薬が、前記回収し、培養し、増殖させた腫瘍特異的な宿主T細胞の前記対象への投与の4日以内に最初に投与される、請求項1〜23のいずれか一項に記載の方法。
- 前記長時間作用型IL−2Rβ−バイアス作動薬が注射により投与される、請求項1〜25のいずれか一項に記載の方法。
- 前記長時間作用型IL−2Rβ−バイアス作動薬の初回投与後少なくとも10日である時点で測定した場合、前記長時間作用型IL−2Rβ−バイアス作動薬の投与がない、ステップ(i)のみによる前記対象の治療時に前記対象の腫瘍部位で保持される腫瘍特異的なエフェクターT細胞の数と比較したときに、又は、同等数のIL−2等価物を達成するために投与されるインターロイキン−2の投与と併用した、ステップ(i)からの前記回収し、培養し、増殖させた腫瘍特異的なT細胞での前記対象の治療時に前記対象の腫瘍部位で保持される腫瘍特異的なエフェクターT細胞の数と比較したときに、より多数の腫瘍特異的なエフェクターT細胞が前記対象の腫瘍部位で保持される結果を得るのに有効である、請求項1〜13及び15〜26のいずれか一項に記載の方法。
- 前記時点が、前記長時間作用型IL−2Rβ−バイアス作動薬の初回投与後、10、11、12、13、14又は15日目である、請求項27に記載の方法。
- 結果として、ステップ(i)又はステップ(ii)のいずれかのみに従い投与が行われる場合に観察される治療に対する応答を超えて促進される有益な応答治療が得られる、請求項1〜26のいずれか一項に記載の方法。
- 治療に対する前記有益な応答が適切な動物モデルに基づく、請求項28に記載の方法。
- 治療の前記方法が、前記長時間作用型IL−2Rβ−バイアス作動薬の投与がない、ステップ(i)単独による前記対象の治療時に、又は、同等数のIL−2等価物を達成するために投与されるインターロイキン−2の投与と併用した、ステップ(i)からの、前記回収し、培養し、増殖させた腫瘍特異的なT細胞での前記対象の治療時に観察されるものと比べて増強される量だけ、前記対象の腫瘍におけるCD4+Treg、CD25+Treg及びFoxP3+Tregsからなる群から選択される制御性T細胞の蓄積を阻害するのに有効である、請求項1〜26のいずれか一項に記載の方法。
- 制御性T細胞の蓄積の前記阻害がインビボ癌モデルにおいて評価される、請求項31に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762465506P | 2017-03-01 | 2017-03-01 | |
US62/465,506 | 2017-03-01 | ||
US201762480971P | 2017-04-03 | 2017-04-03 | |
US62/480,971 | 2017-04-03 | ||
PCT/US2018/020514 WO2018160877A1 (en) | 2017-03-01 | 2018-03-01 | Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020509018A true JP2020509018A (ja) | 2020-03-26 |
JP2020509018A5 JP2020509018A5 (ja) | 2021-04-08 |
Family
ID=63371348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019547077A Pending JP2020509018A (ja) | 2017-03-01 | 2018-03-01 | 養子細胞移植療法と併せてインターロイキン−2受容体α,β−選択的作動薬を用いる免疫療法的治療方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11318164B2 (ja) |
EP (1) | EP3589303A4 (ja) |
JP (1) | JP2020509018A (ja) |
KR (1) | KR20190121773A (ja) |
CN (1) | CN110366421A (ja) |
AU (1) | AU2018227810A1 (ja) |
CA (1) | CA3055040A1 (ja) |
IL (1) | IL269015A (ja) |
MX (1) | MX2019010382A (ja) |
WO (1) | WO2018160877A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
JP7460609B2 (ja) | 2018-05-14 | 2024-04-02 | ウェアウルフ セラピューティクス, インコーポレイテッド | 活性化可能なインターロイキン-2ポリペプチド及びその使用方法 |
AU2019271149B2 (en) | 2018-05-14 | 2023-07-13 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
MX2021013766A (es) | 2019-05-14 | 2022-02-21 | Werewolf Therapeutics Inc | Restos de separacion y metodos de uso de los mismos. |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
CN113121670B (zh) * | 2020-01-15 | 2022-11-22 | 天津键凯科技有限公司 | 二取代peg化白细胞介素2及其制备方法、应用 |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
WO2023202035A1 (zh) * | 2022-04-20 | 2023-10-26 | 北京大学宁波海洋药物研究院 | 受体偏向的peg化il-2变体组合及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008544046A (ja) * | 2005-06-16 | 2008-12-04 | ネクター セラピューティックス エイエル,コーポレイション | 分解性結合を有する複合体と該複合体の調製に有益なポリマー試薬 |
JP2014506116A (ja) * | 2010-11-12 | 2014-03-13 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Il−2部分とポリマーとのコンジュゲート |
WO2015125159A1 (en) * | 2014-02-21 | 2015-08-27 | Nektar Therapeutics (India) Pvt. Ltd. | Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody |
WO2015143328A1 (en) * | 2014-03-20 | 2015-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
-
2018
- 2018-03-01 EP EP18760525.8A patent/EP3589303A4/en not_active Withdrawn
- 2018-03-01 AU AU2018227810A patent/AU2018227810A1/en active Pending
- 2018-03-01 MX MX2019010382A patent/MX2019010382A/es unknown
- 2018-03-01 JP JP2019547077A patent/JP2020509018A/ja active Pending
- 2018-03-01 US US16/490,443 patent/US11318164B2/en active Active
- 2018-03-01 CA CA3055040A patent/CA3055040A1/en active Pending
- 2018-03-01 KR KR1020197024673A patent/KR20190121773A/ko not_active Application Discontinuation
- 2018-03-01 CN CN201880014971.8A patent/CN110366421A/zh active Pending
- 2018-03-01 WO PCT/US2018/020514 patent/WO2018160877A1/en unknown
-
2019
- 2019-08-29 IL IL26901519A patent/IL269015A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008544046A (ja) * | 2005-06-16 | 2008-12-04 | ネクター セラピューティックス エイエル,コーポレイション | 分解性結合を有する複合体と該複合体の調製に有益なポリマー試薬 |
JP2014506116A (ja) * | 2010-11-12 | 2014-03-13 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Il−2部分とポリマーとのコンジュゲート |
WO2015125159A1 (en) * | 2014-02-21 | 2015-08-27 | Nektar Therapeutics (India) Pvt. Ltd. | Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody |
WO2015143328A1 (en) * | 2014-03-20 | 2015-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
Non-Patent Citations (5)
Title |
---|
CANCER RESEARCH, vol. Vol. 76, No. 14, Supplement, JPN6022012055, 2016, pages 558, ISSN: 0004900158 * |
CLINICAL CANCER RESEARCH, vol. 22, no. 3, JPN6022012057, 1 February 2016 (2016-02-01), pages 680 - 690, ISSN: 0004900156 * |
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol. 4, Suppl.1:73, JPN6022012056, 16 November 2016 (2016-11-16), pages 327 - 341, ISSN: 0004900157 * |
JOURNAL OF TRANSLATIONAL MEDICINE, vol. 10:169, JPN6022012053, 2012, pages 1 - 12, ISSN: 0004900160 * |
THE JOURNAL OF IMMUNOLOGY, vol. 192, JPN6022012054, 2014, pages 5451 - 5458, ISSN: 0004900159 * |
Also Published As
Publication number | Publication date |
---|---|
AU2018227810A1 (en) | 2019-08-29 |
IL269015A (en) | 2019-10-31 |
US20200016206A1 (en) | 2020-01-16 |
EP3589303A1 (en) | 2020-01-08 |
CA3055040A1 (en) | 2018-09-07 |
KR20190121773A (ko) | 2019-10-28 |
MX2019010382A (es) | 2019-10-22 |
EP3589303A4 (en) | 2020-11-25 |
US11318164B2 (en) | 2022-05-03 |
CN110366421A (zh) | 2019-10-22 |
WO2018160877A1 (en) | 2018-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11318164B2 (en) | Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy | |
ES2872848T3 (es) | Agonistas selectivos de IL-2Rbeta en combinación con un anticuerpo anti-CTLA-4 o un anticuerpo anti-PD-1 | |
US20190275133A1 (en) | Immunotherapeutic tumor treatment method | |
KR101294290B1 (ko) | 예방 또는 치료를 위해 제i류 주조직 적합성복합체〔mhc〕-제한 에피토프에 대한 면역 반응을 유발,향상 및 지속하는 방법 | |
JP2022521792A (ja) | 癌を治療するための免疫療法的併用 | |
JP2005523277A (ja) | 癌の治療 | |
ES2877090T3 (es) | Receptor de antígenos quiméricos y células T en las que se expresa el receptor de antígenos quiméricos | |
JP2021066748A (ja) | IL−2Rβ選択的作動薬と長時間作用型IL−15作動薬との併用 | |
US20210154277A1 (en) | Immunotherapeutic combination for treating cancer | |
US20140286906A1 (en) | Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases | |
US20230158164A1 (en) | Method for enhancing cellular immunotherapy | |
US20230181633A1 (en) | Methods of treating cancer using a combination of tumor membrane vesicles and metformin | |
EP2852611B1 (en) | Novel melanoma antigen peptide and uses thereof | |
CA2990893C (fr) | Peptides immunogenes de preprocalcitonine | |
Mach | Role of the cytokine GM-CSF in cell-based anti-tumor immunity: learning from murine models to engineer new therapeutic strategies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220328 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220627 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221019 |